TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?
Merkesdal
Sonja
S
Division of Rheumatology, Hannover Medical School, Carl-Neuberg-Str. 1, 30623 Hannover, Germany. merkesdal.sonja@mh-hannover.de
Zeidler
Henning
H
D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha